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Summary Despite the progress achieved in conventional treatment modalities, heart failure
remains a major cause of mortality and morbidity. The identiﬁcation of novel signaling path-
ways has provided a solid scientiﬁc rationale which has stimulated preclinical development of
gene-based therapies for heart failure. Advances in somatic gene transfer technologies have
been crucial to the advent of the ﬁrst human clinical trials which are currently in progress. As
these and other trials of gene transfer-based therapies are initiated, these approaches have
generated excitement and hope for novel treatments for cardiovascular disease. In this review,
we present a summary of advancements in construction of different vectors and methods of
delivery that have been used for speciﬁc myocardial gene delivery. In addition, we will show
results from studies focusing on the use of gene therapy to target heart failure mechanisms
in animal models of cardiac dysfunction. Finally, we discuss the limited but highly promising
results from clinical studies that have served as catalysts to translate preclinical achievements
towards new treatment modalities for heart failure.
© 2010 Elsevier Masson SAS. All rights reserved.MOTS CLÉS
Thérapie génique ;
Insufﬁsance
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Résumé L’insufﬁsance cardiaque demeure une cause majeure de mortalité et de morbidité
malgré le progrès dans les modalités de traitement conventionnel. L’identiﬁcation de nouveaux
mécanismes de signalisation a formé une base scientiﬁque solide pour développer le traite-
ment génétique de l’insufﬁsance cardiaque. Le succès des nouvelles technologies de transfert
génétique a été crucial pour l’initiation des premiers essais cliniques qui sont actuellement en
cours. Ces derniers génèrent beaucoup d’enthousiasme et un espoir de découvrir de nouvelles
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percées thérapeutiques dans le domaine des maladies cardiovasculaires. Dans cet article, nous
présentons un résumé de l’évolution dans la construction des différents vecteurs et des méth-
odes de livraison utilisés pour le transfert génétique au myocarde. Nous montrerons aussi des
résultats d’expériences de traitement génétique dans des modèles animaux de dysfonction-
nement cardiaque. Finalement, nous discuterons les premiers résultats d’essais cliniques qui
promettent de lancer la course de la thérapie génétique dans le traitement de l’insufﬁsance
cardiaque chez l’homme.
© 2010 Elsevier Masson SAS. Tous droits réservés.
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AV adeno-associated virus
C adenylyl cyclase
-AR beta adrenergic receptor
RK G protein-coupled receptor kinase
F heart failure
-1 (protein phosphatase) inhibitor-1
CX sarcolemnal sodium/calcium exchanger
LN phospholamban
P protein phosphatase
ERCA sarcoplasmic/endoplasmic reticulum calcium
ATPase
R sarcoplasmic reticulum
Despite the advances in conventional pharmacology,
mplantable devices and surgery, heart failure (HF) remains
ne of the leading causes of mortality in contemporary soci-
ties. There is an ongoing need to explore novel and more
romising approaches targeting the HF pathobiology. Over
he past decades, advancements in somatic gene transfer
elivery have transformed cardiovascular gene therapy from
futuristic fantasy to a scientiﬁc reality.
This review focuses on the multiple applications of gene
herapy in HF. The ﬁrst part will serve as an overview of
he principal types of vectors used in gene therapy. The fol-
owing section will be a synopsis of the various methods of
ene delivery. We will then discuss the different contem-
orary targets within the cardiac myocyte. The last part
ill present early results of the ﬁrst in-human clinical trial
phase 1) of gene therapy in patients with HF. Far from being
omplete, this article emphasizes the most explored molec-
lar techniques used in a ﬁeld which, although remains in its
nfancy, promises to offer a breakthrough that might change
he dismal history of heart failure.
iral vectors for gene transfer
lassical models of gene therapy rely on recombinant
rotein expression. In contrast, RNA interference (RNAi)
herapy is a novel technology that uses short regulatory
NA sequences to modulate gene expression as its basic
rinciple. Successful use of those strategies for heart fail-
re requires efﬁcient myocardial transduction and long-term
ransgene expression. Viral vectors have been shown to be
learly superior to non-viral vectors such as plasmid DNA,
iposome-DNA and polymer-DNA complexes. They consist of
genetic material surrounded by a capsid that interacts
g
b
n
with speciﬁc cell surface receptors to allow binding, inter-
alization and delivery of the genome to the nucleus of the
arget cell. In this part, we will brieﬂy review the character-
stics of the three most commonly used viral vector families
hich are adenovirus, lentivirus and adeno-associated virus.
able 1 summarizes the advantages and limitations of each
ne of these families.
denoviral vectors
denoviruses are double-stranded DNA viruses capable of
arrying large genes of up to 30 kilobase pairs. They bind to
he Coxsackie-Adenovirus receptors located on the plasma
embrane and interact with cell surface integrins allow-
ng viral endocytosis. Adenoviruses deliver and express
heir genomes within the nucleus of both dividing and
on-dividing cells. Recombinant human adenoviruses are
elatively cheap to produce in high titers and have a broad
ropism to target cells especially within the cardiovascular
ystem, which makes them widely used in myocardial gene
herapy.
However, the use of adenoviruses is limited by a sig-
iﬁcant immune response that results in clearance of the
ransduced cells [1] and transient gene expression lasting
0 to 14 days in animal models [2]. The immune reaction
estructs the cells enclosing the virus which in practice can
esult in adenoviral-induced myocarditis [3]. Adenoviruses
ave also an innate tropism to multiple human tissues which
an result in transfection of unintended host tissues. Multi-
le side effects including fever, chills, shivering, myalgias
nd even death are reported in clinical trials [4]. Another
ajor disadvantage is the presence of either preexisting or
e novo formed antibodies that neutralize the adenoviral
ectors limiting their transfection capacity.
entiviral vectors
entiviruses belong to the Retroviridae family. The most
ommonly used lentiviral vector is based on the human
mmunodeﬁciency virus type 1 (HIV-1). Lentiviruses have the
apacity to transduce non-dividing cells, a feature required
or targeting cardiovascular tissue. They can carry genes up
o 8 kilobase in size. The efﬁciency of myocardial transfec-
ion is similar to adenoviruses but with longer duration of
ene expression.
Due to the derivation from HIV, lentiviruses raised
iosafety concerns that were addressed by modifying the
ative vector. The modiﬁcations include deletion of all the
ild-type HIV accessory proteins and modiﬁcation of the
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Table 1 Comparison of major viral vector systems.
Vectors Adenovirus AAV Lentivirus
Functional titer (per mL) Up to 1012 Up to 1010 Up to 109
Genome dsDNA ssDNA ssRNA
Insert capacity 7 to 30 kb 4.8 kb 7 kb 10 kb
Integration No Yes - chromosome
19 - wild type
AAV
No -recombinant
AAV
Pseudo-random
Pattern of transgene expression Transient Long-term Long-term
Cell-cycle dependent transduction No No No
Host/vector interactions Cytotoxic and Minimally Minimally immunogenic
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Clinical trial approved Yes
long terminal repeat (LTR) sequences of the vector [5].
These adjustments render the manufactured lentiviruses
unable to replicate and minimize the risk of gene expression
through recombination of a wild-type LTR with the therapeu-
tic vector.
Adeno-associated virus vectors
Adeno-associated viruses (AAVs) are single-stranded DNA
agents, members of the Parvovirus family. They are non-
pathogenic with minimal immunogenicity and sustained
expression which might be related to their inability to infect
antigen-presenting cells. AAVs enter cells by endocytosis
after binding to speciﬁc cell surface receptors. They are
capable of transfecting non-dividing cells similar to car-
diomyocytes. There are 11 identiﬁed serotypes of AAV, of
which AAV1, 6, 8 and particularly 9 have excellent tropism
for the heart [6]. The recombinant AAVs (rAAVs) used for
gene therapy persist as episomal DNA in target cells instead
of inserting into the human genome. This should render the
risk of insertional mutagenesis from rAAVs negligible [7]. On
the other hand, one of the major disadvantages of AAVs is
their limited genome packaging capacity of 4.7 kilobase. In
addition, since AAVs have single-stranded DNA, they require
synthesis of a complementary strand before transcription
of the delivered gene can happen. Thus, the onset of gene
expression is delayed and peak levels are attained between
2 and 4 weeks postmyocardial delivery [8]. Moreover, human
exposure to AAV capsid through natural infection or vector
administration can result in production of all subclasses of
Immonuglobulin G antibodies [9]. Natural exposure to AAVs
results in the presence of neutralizing antibodies (NAbs)
against some serotypes in about 20—40% of the popula-
tion. Those antibodies, together with those generated by
the immune system in response to previous treatment with
similar viral vectors limit the efﬁciency of gene therapy with
AAVs [10].
Despite their relatively high cost of production, rAAVs are
currently considered to be an agent of choice for myocar-
dial gene therapy. To date, there have been more than 20
trials using AAV vectors including the ﬁrst clinical trial of
AAV1/SERCA2a in advanced heart failure, all of which found
no unexpected safety concerns [11].
R
P
v
aimmunogenic
Yes No
ethods of vector delivery
n addition to the major advances in engineering vehicles
or myocardial gene therapy, the last two decades have also
itnessed development of novel strategies for gene delivery
hat we will brieﬂy discuss in this section. Catheterization
as been used to target the myocardium by antegrade intra-
oronary injection, retrograde coronary vein infusion and
y direct endomyocardial or pericardial injection. Surgical
elivery to the myocardium or pericardium can also be used
nd might be the preferred route in certain clinical settings.
ntegrade injection
ntegrade injection in the coronary circulation is charac-
erized by its capacity to homogenously deliver the vector
o the myocardium. Agents increasing permeability of the
ascular bed such as substance P, histamine or vascular
ndothelial growth factor, have been successfully used to
mprove the transduction efﬁciency of this technique [12].
ercutaneous coronary venous blockade can also enhance
ene delivery when performed simultaneously with ante-
rade coronary injection [13]. In addition, the V-focus
ystem [14] is a recently developed percutaneous modal-
ty that separates the coronary and systemic circulations
o establish a closed circuit between the coronary arter-
es and the coronary sinus. The procedure involves three
ercutaneous catheters, two of which to perfuse the right
nd left coronary arteries and a third catheter with a bal-
oon to occlude the coronary sinus. The perfusate circulates
hrough an extracorporeal membrane oxygenation system
hat provides adequate myocardial oxygen supply. The V-
ocus system delivers the vector almost exclusively to the
yocardium, keeping in mind however that less than 10% of
he coronary circulation ﬂow continues to communicate with
he cardiac chambers and the systemic circulation through
he Thebesian veins.etrograde injection
ercutaneous retrograde delivery of vectors in coronary
eins has been validated in large animal models and
chieved gene expression comparable to antegrade delivery
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15]. The pressure resulting from antegrade ﬂow is a limit-
ng factor that is eliminated by simultaneous brief blockade
f the coronary artery ﬂow. Knowing that coronary veins
emain mostly disease-free, the retrograde route is particu-
arly useful when antegrade delivery is limited by a diseased
rterial coronary circulation.
irect injection
irect injection of the vector into the myocardium can be
chieved surgically or percutaneously. It overcomes numer-
us potential drawbacks that can be encountered with the
ntravascular route including the ﬁrst-pass effect of the liver
nd spleen, the effect of neutralizing antibodies, the T-cell
esponse and the impermeability of the endothelial barrier.
urgical gene transfer can be performed through a subxiphis-
ernal or transthoracic approach and can be an attractive
pproach when the myocardium is easily accessible as during
p
t
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Table 2 Potential gene therapy targets for heart failure.
Potential gene therapy targets for heart failure.
System Gene Mechanism
-adrenergic system 2-AR Increases adenylyl cyclas
activity
GRK2 Abolishing GRK2 reverses
agonist-dependent
desensitization of -ARs
AC VI Full mechanism remains
Increases cAMP generatin
capacity Improves
phosphorylation of cTnI
Ca2+ cycling proteins SERCA2a Improves cytosloic Ca2+
regulation
PLN PLN inhibition relieves in
effect on SERCA2a expre
I-1 Inhibits PP1 leading to
phosphorylation of PLN a
increased SERCA2a activ
S100A1 Enhances the activity of
ryanodine receptors and
SERCA2a
Cell death Bcl-2 Enhances cell survival
I-1, S100A1 Regulation of calcium ha
and decreased endoplasm
reticulum stress
2-AR Gi-mediated pathwayM.T. Njeim, R.J. Hajjar
ardiothoracic surgeries. Catheter-based needle endomy-
cardial injection can be performed with several types of
atheters and under different guidance modalities includ-
ng ﬂuoroscopy, electromagnetism and 3D mapping systems
16,17]. Both the surgical and the percutaneous approaches
ave limited vector delivery secondary to the restricted area
f injection and the leakage at the site of the myocardial
njection [18].
ericardial delivery
he pericardial sac is a closed space in close proximity
o the myocardium and is accessible to both surgical and
ercutaneous delivery. Vectors in this space preferentially
ransduce the pericardial cells with minimal myocardial
xpression. Administration of collagenase and hylauronidase
long with the vector can disrupt the pericardial cellular
ining and extracellular matrix which improves myocardial
Outcome Clinical trials
e Positive inotropic effect No
Positive inotropic effect and
improved ventricular
remodeling (inconsistent
results)
No
unclear
g
Positive inotropic effect
Improved ventricular
remodeling
Reduced apoptosis
No
Positive inotropic effect
Improved ventricular
remodeling
Decreased oxygen cost of LV
contractility
Decreased incidence of
ischemic ventricular
arrhythmias
In progress
hibitory
ssion
Improved systolic and
diastolic function
(inconsistent results)
No
nd
ity
Positive inotropic effect
Improves diastolic function
Ameliorates
ischemia/reperfusion-
induced
injury
No
Positive inotropic effect
Improved ventricular
remodeling
No
Anti-apoptotic and positive
inotropic effect in
ischemia/reperfusion
No
ndling
ic
Anti-apoptotic effect No
Anti-apoptotic effect No
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transduction. This is however associated with a higher
systemic contamination and local inﬂammatory changes
[19]. In addition to the surgical techniques, a percutaneous
approach allows a safe and effective pericardial access
appropriate for the delivery of therapeutic agents [20].
The optimal method of delivery depends largely on the
proportion of target tissue to be genetically modiﬁed. Focal
transduction might be desired to salvage an ischemic area
whereas diffuse gene expression is more likely to reverse
global myocardial dysfunction.
Heart failure gene therapy targets
The last 20 years witnessed signiﬁcant evolution in our
understanding of the pathophysiology of heart failure in
its molecular and cellular dimensions which broadened the
scope of interventions available for gene therapy. Far from
being complete, we will discuss in this part some of the most
important systems targeted to restore the function of failing
cardiomyocytes. In Table 2, we list those systems along with
their corresponding genes and therapeutic effects.Targeting the -adrenergic system
Cardiac beta-adrenergic receptors (-AR) are mainly 1 sub-
type linked to a stimulatory heterotrimeric G protein (Gs)
O
O
w
o
Figure 1. Excitation-contraction signaling in cardiomyocytes with emp
dling (purple) and -adrenergic (blue) systems is illustrated. AC: aden
receptor; I-1: (protein phosphatase) inhibitor-1; cAMP: cyclic adenosine
tein; NCX: sarcolemnal sodium/calcium exchanger; PKA: protein kinase
receptor; SERCA: sarcoplasmic/endoplasmic reticulum calcium ATPase; S481
hich stimulates adenylyl cyclase (AC) to produce a second
essenger, cyclic adenosine monophosphate (cAMP). The
atter acts through a series of intracellular signals involv-
ng a third messenger protein kinase A (PKA) which in turn
hosphorylates a number of targets including troponin-I and
-type Ca2+ channels responsible for the physiologic effects
f -AR stimulation (Fig. 1). 2 receptors are also present,
hough to a lesser extent, in the heart. They are linked to
s but also to an inhibitory G protein (Gi) which is respon-
ible for inhibition of adenylyl cyclase. It is proposed that
2 receptors are more strongly coupled to Gs except in HF
here their effect on Gi is increased. Chronic heart failure
s associated with increased sympathetic outﬂow. Although
his seems to be initially a compensatory mechanism, it is
ore deleterious in the long term. The -adrenergic system
s affected by multiple alterations including -ARs down-
egulation, upregulation of -ARs kinase and increased Gi
unction. These alterations lead to desensitization of the
-ARs and decreased signaling through their pathway.
Several gene-based experiments tested the hypothesis
hat genetic manipulation of the myocardial -AR system
an enhance cardiac function.verexpression of -AR
verexpression of -AR was initially tested as a simple
ay to overcome -AR downregulation. Transgenic mice
verexpressing the human 1-ARs suffered from severe
hasis on targets for gene therapy. Interplay between calcium han-
ylyl cyclase; ATP: adenosine triphosphate; -AR: beta adrenergic
monophosphate; Gs: stimulatory G protein; Gi: inhibitory G pro-
A; PLN: phospholamban; PP: protein phosphatase; RyR: ryanodine
R: sarcoplasmic reticulum.
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ardiomyopathy [21]. This ﬁnding reinforces the hypothesis
hat -AR downregulation is a protective mechanism in the
ailing heart. In contrast, mice with cardiac overexpression
f 2-AR demonstrated increased basal myocardial adenylyl
yclase activity with increased left ventricular function
22]. Studying transgenic mice with different levels of 2-AR
verexpression suggests that the heart tolerates enhanced
ontractile function via 60-fold 2-AR overexpression with-
ut detriment over more than 1 year and that higher levels
f expression result in either aggressive or delayed ﬁbrotic
ardiomyopathy [23]. Based on those ﬁndings suggesting
potential beneﬁt of 2-AR enhancement, adenovirus-
ediated 2-AR gene delivery was studied in larger animals.
oth direct and intracoronary myocardial delivery of ade-
ovirus containing the human 2-AR transgene resulted in
nhanced cardiac performance in rabbits [24,25].
nhibition of G protein-coupled receptor kinases
GRKs)
he interaction between activated -ARs and G proteins is
egulated by kinases that modulate the receptor activity by
hosphorylation of its carboxyl terminus. Agonist-dependent
esensitization is mediated by a family of GRKs which
hosphorylate the agonist-occupied receptors resulting in
unctional uncoupling. GRK2 is the most expressed GRK in
he heart. It has been implicated in the pathogenesis of
ysfunctional cardiac -AR signaling accounting for a dele-
erious activity in the failing heart [26]. There is controversy
n the literature about the results of abolishing GRK2 activ-
ty. However, a recent study using mice in which HF was
nduced by a myocardial infarction, showed that selective
RK2 ablation 10 days postinfarction resulted in increased
urvival, halted ventricular remodeling and enhanced car-
iac contractile performance [27]. A peptide termed ARKct
apable of inhibiting GRK2 mediated -AR desensitization
as been evaluated in vivo in animals. A study using intra-
oronary adenovirus-mediated ARKct transgene delivery to
abbits 3 weeks after induced myocardial infarction demon-
trated a marked reversal of ventricular dysfunction [28].
ctivation of cardiac AC expression
lthough detrimental outcomes were demonstrated with
ultiple elements of the -adrenergic system used to
mprove the expression of cAMP, activation of AC type VI
AC VI) seems to have a unique favorable proﬁle. Overex-
ression of AC VI in transgenic mice resulted in improved
ardiac function in response to adrenergic stimulation
long with increased cAMP production in isolated cardiac
yocytes. Importantly, AC VI had a neutral effect on basal
eart function and was not associated with any struc-
ural heart abnormalities [29]. This is in contrast with the
teady increase in cAMP and the negative cardiac outcomes
btained after gene transfer of -AR or Gs [30,31]. Increased
xpression of AC VI in a mice model of acute myocardial
nfarction resulted in decreased mortality and preservation
f LV contractility. In addition to improving cAMP generation,
xpression of AC VI in this particular study was associated
ith a favorable effect on Ca2+ handling [32]. In a pacing
odel of HF in pigs, intracoronary delivery of adenovirus
ncoding AC VI resulted in improved LV function and remod-
ling, associated with increased cAMP generating capacity
i
i
b
t
oM.T. Njeim, R.J. Hajjar
33]. The favorable effects of AC VI in preclinical studies
re encouraging and this approach is currently under inves-
igation for initiation of clinical trials in patients with HF
34].
Despite some controversy in the literature, there is a
arge volume of preclinical studies showing unequivocally
hat gene therapy targeting the -AR system can be of ther-
peutic value in the treatment of HF. Until more studies
nd especially clinical trials take place, targeting the -AR
ystem is viewed as a promising ﬁeld.
argeting Ca2+ cycling proteins
a2+ plays a crucial role in contraction and relaxation phases
f the cardiac cycle (Fig. 1). Ryanodine receptors (RyR)
re proteins forming a link between the T tubules in the
ardiomyocytes and the sarcoplasmic reticulum (SR). In a
rocess known as ‘‘Ca2+ induced Ca2+ release’’, depolar-
zation activates voltage-operated L-type Ca2+ channels of
he T tubule to allow Ca2+ entry into the cardiomyocyte.
a2+ reaches the RyR protein modifying its molecular conﬁ-
uration which in turn opens the Ca2+ release channel of
he SR releasing Ca2+ into the cytosol. This process greatly
ncreases the concentration of Ca2+ in the cytosol allowing
t to interact with troponin C triggering the contraction pro-
ess. Relaxation occurs when Ca2+ detaches from troponin C
nd is either taken up by the SR via the action of sarcoplas-
ic/endoplasmic reticulum Ca2+ ATPase (SERCA) or extruded
rom the cardiac cell by the sarcolemnal Na+/Ca2+ exchanger
NCX). In humans, approximately 75% of Ca2+ is removed by
ERCA. This protein is a Ca2+-ATP-dependent pump present
n SR membrane and protruding into the cytosol. It exists
n different isoforms, of which SERCA2a is the dominant
ardiac form. This pump transports 2 Ca2+ across the SR
embrane per each ATP used. In comparison, NCX removes
ne cytosolic Ca2+ per each ATP consumed (Na+-K+-ATPase
ses 1 ATP to pump out three Na+ which have passively
ntered the cell in exchange for one Ca2+ via NCX) [35].
hospholamban (PLN) is a protein implicated in regulation
f SERCA2a activity. In its unphosphorylated form, PLN can
nhibit SERCA2a. In contrast, phosphorylation of PLN relieves
ts inhibitory effect and results in increased SERCA2a activ-
ty with improved Ca2+ handling. Protein phosphatase 1
PP1) is a type of serine/threonine phosphatase which has
major role in dephosphorylation of PLN in the heart [36].
n particular, stimulation of the -adrenergic axis induces
hosphorylation of a phosphatase inhibitor Protein-1 (I-1)
esulting in PP1 inhibition and enhancement of myocardial
ontractile function [37]. HF is characterized by multiple
efects in Ca2+-handling proteins with impaired SR Ca2+ load-
ng and release. Reversal of those defects by gene therapy
echniques has shown very promising results. We will review
he main aspects of those novel therapies in this section.
verexpression of SERCA2a
onsistently decreased SERCA2a activity has been identiﬁed
n the failing human hearts [38]. Short-term improvement
n cardiac contractility after gene transfer of SERCA2a has
een demonstrated in HF rats [39]. More importantly, long
erm overexpression of SERCA2a by intracoronary delivery
f AAV carrying SERCA2a has been associated with preserved
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systolic function and improved ventricular remodeling in a
swine volume-overload model of HF [40].
Decreased SERCA2a activity in HF is compensated by
an increase in the extrusion of Ca2+ from the cardiomy-
ocyte into the extracellular space by NCX. As mentioned
above, NCX consumes twice the amount of energy required
for uptake of the same amount of Ca2+ by SERCA2a [35].
Thereby, the altered ratio of SERCA2a/NCX activity in heart
failure can contribute to a deleterious increase in energy
consumption during excitation—contraction coupling. In rats
with failing hearts secondary to diabetes mellitus, SERCA2a
gene transfer was shown to decrease the oxygen expendi-
ture for LV contractility to a normal level, in addition to
restoring normal systolic and diastolic functions [39]. While
-adrenergic agonists improve contractility at the expense
of increasing energy consumption and mortality, SERCA2a
overexpression is a very promising approach to improve mor-
tality by optimizing the mechano-energetic state of the
heart.
Finally, a ﬁrst-in-human clinical trial treating dilated car-
diomyopathy with SERCA2a gene transfer is currently in
progress and will be discussed in the last section of this
review.
PLN inhibition
Another approach to improve Ca2+ handling involves inhi-
bition of PLN. Inconsistent results were reported with PLN
ablation ranging from deterioration of the cardiac function
to restoration of myocardial contractility and Ca2+ home-
ostasis. Silencing of PLN expression in a sheep HF model
resulted in improved SERCA activity along with improved
systolic and diastolic LV function [41]. In addition, infecting
human myocardial cells with an adenovirus encoding for an
antisense of PLN showed an improvement in contraction and
relaxation velocities similar to the beneﬁt seen with aden-
oviral transfer of the SERCA2a gene [42]. In addition to the
above conventional gene therapy strategies, RNAi therapy
was used for the ﬁrst time in a model of cardiac disease,
speciﬁcally in rats with HF, in an attempt to suppress phos-
pholamban expression. A rAAV-RNAi vector generated stable
cardiac production of a regulatory RNA sequence, which in
turn suppressed phospholamban expression. SERCA2a pro-
tein was subsequently increased accompanied by restoration
of systolic and diastolic cardiac function [43].
Active I-1 and Inhibition of PP1
HF is associated with elevated PP1 activity in humans result-
ing in dephosphorylation of PLN [44]. Overexpression of PP1
or ablation of I-1 in murine hearts has been associated with
decreased -AR-mediated contractile responses, depressed
cardiac function and premature death consistent with HF
[45]. Expression of a constitutively active I-1 in transgenic
mice led to PP1 inhibition with increased phosphorylation
of PLN and improved cardiac contractility [37]. A recent
study on transgenic mice expressing active I-1 conﬁrmed the
relationship between phosphorylation of PLN and SERCA2a
activity. I-1 expression ameliorated ischemia/reperfusion-
induced injury by reducing the infarct size and improving
contractile recovery in addition to decreasing biomarkers of
apoptosis and ER stress response [46].
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100A1
100 is a multigenic family of Ca2+-modulated proteins impli-
ated in intracellular and extracellular regulatory activities.
100A1 is the most abundant S100 protein isoform in the
eart. It promotes cardiac contractile and relaxation func-
ion through enhancing the activity of both RYRs and
ERCA2a. Loss of S100A1 in transgenic mice was associated
ith a reduced contractile response to acute -adrenergic
timulation (isoproterenol injection), and a rapid deteriora-
ion of contractile function in response to chronic pressure
verload by thoracic aortic constriction [47]. In a rat cryoin-
arct model of HF, rAAV6-mediated long-term expression of
100A1 resulted in a sustained in vivo reversal of LV dysfunc-
ion and remodeling. In addition, this model showed additive
eneﬁcial effects when compared with and added to phar-
aceutical -AR blockade (using metoprolol), a feature of
igh clinical relevance suggesting that both treatments can
ventually become additive in human heart failure [48].
argeting cell death
poptosis is a process of programmed cell death that
s involved in normal organ development. In a model of
cute ischemia/reperfusion, overexpression of the anti-
poptotic protein Bcl-2, in transgenic mice reduced the
ate of cardiomyocyte apoptosis and improved heart func-
ion [49]. Regulation of Ca2+ handling appears also as a
otential pathway to limit apoptosis. As mentioned in a
revious section, active I-1 expression in a mice model of
schemia/reperfusion improved Ca2+ handling and reduced
poptosis in association with suppressing markers of SR
tress (caspase 12, Grp 78 and Inositol-requiring enzyme
)[46]. S100A1 was also reported to have an anti-apoptotic
ffect when added as an extracellular protein to a culture
f neonatal ventricular cardiomyocytes [50]. On the other
and, the -adrenergic system seems also to be an impor-
ant modulator of apoptosis. Two different studies on
odent cardiac myocytes revealed that 2-AR stimulation
educes apoptosis via a Gi-mediated pathway, whereas
1-AR stimulation enhances apoptosis through a cAMP-
ependent mechanism [51,52].
Despite the early encouraging results in animal studies,
nti-apoptotic strategies face multiple challenges before
eing considered for human trials. There remain some
ncertainties about the reliability of the techniques cur-
ently used to estimate the rate of apoptotic cell death
53]. In addition, loss of the normal cellular regulation role
rovided by apoptosis can generate a serious risk of malig-
ant cellular proliferation and autoimmune injuries. Finally,
hile ischemia/reperfusion injury appears to be amenable
o intervention, it is less clear if other forms of cardiac injury
nd HF can beneﬁt from anti-apoptotic strategies.
In summary, numerous molecular and cellular mecha-
isms incriminated in HF are currently within reach of gene
herapy. The large amount of preclinical experience that
e tried to summarize is an additional proof-of-concept
hat gene therapy, originally envisioned as a treatment for
nherited monogenic diseases, can target acquired polygenic
isorders such as HF. The expanding number of molecular
argets and the innovations in gene-based therapies such as
he recent use of the RNAi strategy are promising indicators
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f the wide therapeutic scope and the high efﬁciency that
ene therapy might potentially achieve. While the preclini-
al data will continue to expand, we are currently witnessing
he birth of HF gene-based therapy in humans.
linical trial
fter several years of preclinical experimentation, the ﬁrst
linical trial of gene therapy in patients with HF was
aunched in the United States in 2007 [54]. Ca2+ upregulation
y percutaneous administration of gene therapy in cardiac
isease (CUPID) is a multicenter trial designed to evaluate
he safety proﬁle and the biological effects of gene trans-
er of the SERCA2a cDNA by delivering a recombinant AAV1
AAV1/SERCA2a) in patients with advanced HF. Participants
n this trial were administered a single intracoronary infu-
ion of AAV1/SERCA2a in an open-label approach. Cohorts
, 2 and 3, of three patients each, received sequentially a
ingle escalating dose of AAV1/SERCA2a. The infusion was
pread over multiple coronary arteries in an attempt to
rovide homogeneous myocardial exposure. 6 to 12 month
ollow-up of these patients showed an acceptable safety
roﬁle. None of the serious adverse events reported was
onsidered to be secondary to the study drug. Improvement
as detected in several patients, reﬂected by symptomatic
ﬁve patients), functional (four patients), biomarker (two
atients) and LV function/remodeling (six patients) parame-
ers. In contrast to conventional inotropic agents, the study
rug was associated with improvement in VO2 max which
ccording to the authors may reﬂect the effect of SERCA2a
n restoring an optimal mechano-energetic state of the
eart. Although this is a phase 1 study involving a small
umber of patients, early results found that AAV1/SERCA2a
reatment conferred quantitative biological beneﬁt in every
atient without pre-existing Nabs. This strongly supported
he initiation of phase 2 of the trial which is a randomized,
ouble-blind, placebo controlled, parallel-group, and dose
anging trial. Participants are currently being recruited and
he estimated completion date of this phase is January 2010.
The results of this trial, in addition to larger trials of the
ame type, are certainly eagerly-awaited and will hopefully
rovide the scientiﬁc foundation to support gene therapy as
treatment modality for HF in humans.
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